Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Schindler

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Christoph Schindler
Therapeutic Advances in Cardiovascular Disease|November 18, 2009
New players in the field of antiplatelet and anticoagulant therapy in coronary heart disease - current therapeutic issues and hot topicsChristoph Schindler
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGETChristoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the fieldChristoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?Christoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
New therapeutic efforts and upcoming developments in the field of diabetes medicine and endocrinologyChristoph Schindler
Deutsche Medizinische Wochenschrift (1946)|June 20, 2006
[Pharmacologic interactions as the cause of a loss of effectiveness of local anesthetics]Ulf Maywald, Christoph Schindler
Expert Opinion on Pharmacotherapy|December 25, 2009
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartanPeter Bramlage, Christoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|April 20, 2016
Clinically and pharmacologically relevant interactions of antidiabetic drugsMarcus May, Christoph Schindler
Future Cardiology|October 7, 2009
Olmesartan for the treatment of arterial hypertensionChristoph Schindler, Carlos M Ferrario
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Christoph Schindler
Therapeutic Advances in Cardiovascular Disease|November 18, 2009
New players in the field of antiplatelet and anticoagulant therapy in coronary heart disease - current therapeutic issues and hot topicsChristoph Schindler
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGETChristoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the fieldChristoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?Christoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|November 14, 2012
New therapeutic efforts and upcoming developments in the field of diabetes medicine and endocrinologyChristoph Schindler
Deutsche Medizinische Wochenschrift (1946)|June 20, 2006
[Pharmacologic interactions as the cause of a loss of effectiveness of local anesthetics]Ulf Maywald, Christoph Schindler
Expert Opinion on Pharmacotherapy|December 25, 2009
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartanPeter Bramlage, Christoph Schindler
Therapeutic Advances in Endocrinology and Metabolism|April 20, 2016
Clinically and pharmacologically relevant interactions of antidiabetic drugsMarcus May, Christoph Schindler
Future Cardiology|October 7, 2009
Olmesartan for the treatment of arterial hypertensionChristoph Schindler, Carlos M Ferrario
Pageof 7